Business
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for
About this update from Passage Bio, Inc.
[{"type":"text","content":"Dosed first patient in Cohort 2 and completed dosing of Cohort 3 in Imagine-1 clinical trial for GM1 gangliosidosis; interim safety and biomarker data for both cohorts expected in 2H22Dosed first patient in Cohort 1 in GALax-C clinical trial in infantile Krabbe disease; interim safety and biomarker data expected by year-end 2022Submitted IND for Phase 1/2 clinical program of PBML04 for metachromatic leukodystrophy Completed strategic prioritization to extend cash runway into 2Q24Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, May 16, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the first quarter ended March 31, 2022 and provided recent business highlights. “We remain focused on execution across our ongoing clinical programs and are excited to have dosed additional patients in our Imagine-1 trial for GM1 gangliosidosis as well as the first patient in our GALax-C trial for infantile Krabbe disease,” said Bruce Goldsmith, Ph.D., president and chief executive officer of Passage Bio. “We look forward to reporting data as these programs advance throughout 2022, including additional clinical and biomarker data from Cohort 1 in Imagine-1 at the ASGCT conference this week. We continue to open additional clinical sites for our FTD program and expect to dose the first patient in mid-2022.” “We are thrilled to have recently submitted an IND for PBML04 in metachromatic leukodystrophy, our third rare, pediatric, lysosomal storage disorder program,” Dr. Goldsmith added. “We also recently completed prioritization of our additional pipeline programs as part of our strategic initiatives to extend our cash runway into the second quarter of 2024 and look forward to continuing to advance our programs in amyotrophic lateral sclerosis and Huntington’s Disease and our ongoing exploratory research programs in Alzheimer’s Disease and temporal lobe epilepsy. Rights to our programs for Canavan disease, Charcot-Marie-Tooth Type 2A and Parkinson’s disease have been returned to the University of Pennsylvania allowing for the future development of these programs. We remain deeply committed to our mission of developing transformative therapies for people with dev...